News | July 22, 2021
Gland Pharma Q1FY22 consolidated PAT rises to Rs. 350.65 Cr
The company reported total income of Rs.1215.73 crores during the period ended June 30, 2021.
The company reported total income of Rs.1215.73 crores during the period ended June 30, 2021.
The company has reported total income of Rs.45.29 crores during the 12 months period ended March 31, 2021
The company reported total income of Rs.263.60 crores during the 12 months period ended March 31, 2021
The company has posted net profit / (loss) of Rs.5.33 crores for the 12 months period ended March 31, 2021
The company has posted net profit of Rs.1.09 crores for the 12 months period ended March 31, 2021
The company has reported total income of Rs.355.43 crores during FY 2020-21
The company has posted net profit of Rs.12.12 crores for the 12 months period ended March 31, 2021
Fingolimod is an immunomodulating drug. It is a sphingosine 1-phosphate receptor modulator indicated for the treatment of relapsing forms of multiple sclerosis
The end user can validate the authenticity of the product by scanning the digital code with the help of a smartphone letting the end user know it is safe to use
The company is exploring all legal options to challenge the award.
Subscribe To Our Newsletter & Stay Updated
